ID   NZM040
AC   CVCL_D832
SY   NZM40; NZM 040
DR   BioSample; SAMN07624446
DR   BioSample; SAMN14558337
DR   cancercelllines; CVCL_D832
DR   CBA; CBA-1381
DR   Cosmic; 1660293
DR   Cosmic; 2007673
DR   Cosmic; 2406332
DR   Wikidata; Q54931573
RX   PubMed=20041153;
RX   PubMed=22475322;
RX   PubMed=23658559;
RX   PubMed=23755070;
RX   PubMed=24455489;
RX   PubMed=32567790;
CC   Doubling time: 38 hours (CBA=CBA-1381).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Homozygous (PubMed=23658559; PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=23755070; PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg249_Thr253del; Zygosity=Unspecified (PubMed=23755070).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
ST   Source(s): CBA=CBA-1381; PubMed=32567790
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 17,18
ST   D19S433: 11,13
ST   D21S11: 27,34.2
ST   D2S1338: 20
ST   D3S1358: 17,18
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 14
ST   FGA: 23,24
ST   TH01: 8,9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461; PMCID=PMC2794539;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:e8461.1-e8461.11(2009).
//
RX   PubMed=22475322; DOI=10.1186/1471-2407-12-141; PMCID=PMC3352269;
RA   Kim J.E., Stones C.J., Joseph W.R., Leung E.Y., Finlay G.J.,
RA   Shelling A.N., Phillips W.A., Shepherd P.R., Baguley B.C.;
RT   "Comparison of growth factor signalling pathway utilisation in
RT   cultured normal melanocytes and melanoma cell lines.";
RL   BMC Cancer 12:141.1-141.10(2012).
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=23755070; DOI=10.3389/fgene.2013.00097; PMCID=PMC3668138;
RA   Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.;
RT   "Heterogeneity of expression of epithelial-mesenchymal transition
RT   markers in melanocytes and melanoma cell lines.";
RL   Front. Genet. 4:97.1-97.8(2013).
//
RX   PubMed=24455489; DOI=10.3389/fonc.2013.00333; PMCID=PMC3888952;
RA   D'mello S.A.N., Flanagan J.U., Green T.N., Leung E.Y.,
RA   Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J.,
RA   Shaw J.H.F., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C.,
RA   Kalev-Zylinska M.L.;
RT   "Evidence that GRIN2A mutations in melanoma correlate with decreased
RT   survival.";
RL   Front. Oncol. 3:333.1-333.9(2014).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//